ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT01067820
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 324 participants
- Registry
-
NCT01067820
-
- Other papers using this trial's data
- Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Argentina, Belgium, Brazil, Hungary, Netherlands, Poland, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01067820. Randomized; triple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
- Acronym
- ASSURE I
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- RVX000222
- Intervention (Drug)
- Placebo RVX000222
- Lead sponsor
- Resverlogix Corp
- Collaborator
- The Cleveland Clinic
Record details
- Record id
cardio:ct-nct01067820- Content hash
649aa73d68855a3b481c19f4707da3951e61a56dcd1f0efa4e16976d64b7529d